🔎 Trials Near Me

Home › T-Cell Lymphoma

Pag-aaral pangklinika para sa T-Cell Lymphoma na nagre-recruit sa U.S.

35 pag-aaral para sa T-Cell Lymphoma ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.

Mga lungsod na may pinakamaraming pag-aaral

Ayos sa estado

Mga pag-aaral na kamakailan lamang in-update

Opisyal na teksto ng pag-aaral (English)

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT04752826

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT05010005

A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT06854653

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT04803201

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT04104776

Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms

Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 12, 2026 · NCT07382817

CD45BE-HSPC + CART-45 Cells

Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 10, 2026 · NCT07451054

Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)

Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT07750886

Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas

Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 5, 2026 · NCT07293403

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 31, 2026 · NCT03011814

Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma

Nagre-recruitPhase 1
Edad 0 hanggang 29 · Lahat ng kasarian · Na-update Hul 7, 2026 · NCT06934382

Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma

Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT03501576

Allo HSCT Using RIC and PTCy for Hematological Diseases

Nagre-recruitPhase 2
Hanggang edad 75 · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT05805605

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 1, 2026 · NCT06508463

CD4CAR for CD4+ Leukemia and Lymphoma

Nagre-recruitPhase 1
Edad 12 pataas · Lahat ng kasarian · Na-update Hun 24, 2026 · NCT03829540

A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 16, 2026 · NCT05463263

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 11, 2026 · NCT05313243

Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas

Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 5, 2026 · NCT07278856

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Nagre-recruitObservasyonal na pag-aaral
Edad 0 hanggang 38 · Lahat ng kasarian · Na-update Hun 4, 2026 · NCT06131801

A Registry for People With T-cell Lymphoma

Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update May 20, 2026 · NCT05978141

Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.